Inclusion Criteria:  18-80 years of age; Patients with stage ⅢB-IV NSCLC are diagnosed by histopathology and cytology; Patients' tumor tissues are unresectable as assessed by the investigator; Have measurable disease based on RECIST 1.1; Driver gene (EGFR/ALK/ROS1) is negative; Patients who are receiving first-line platinum-doublet chemotherapy with remaining no fewer than 4 therapeutic cycles; Patients in chemotherapy who combined with other systemic therapy (including but not limited to immune checkpoint inhibitors and anti-vascular targeted drugs) are not suitable, but with radiotherapy can be permitted; During chemotherapy cycles, patients who take prior treatment with anticancer Chinese medicine less than 4 weeks can be enrolled after stopping medication. If administration time is longer than 4 weeks, at least 4 weeks washout period should be performed; Patients are diagnosed with Qi-yin deficiency by the Syndrome Differentiation of Traditional Chinese Medicine; The expected survival time ≥3 months; The subjects volunteer to sign the informed consent.  Exclusion Criteria:  Allergy or hypersensitivity to ingredients of the study treatment formulation; Pregnant or lactating women; Patients with multiple brain metastases, multiple bone metastases and liver metastases, which have great influence on survival times； Patients are enrolling in other therapeutic trials; The investigator does not consider the participant to be eligible for this study.